Image: CC/L. academia
1. In patients with anemia and chronic kidney disease, treating with epoetin alfa to a lower hemoglobin target was associated with significantly reduced incidence of the composite event (death, MI, hospitalization for CHF, and stroke).
2. Achieving the lower hemoglobin target required significantly lower doses of epoetin alfa.